地拉罗司是不是化疗药？

It is an oral iron chelator used to treat iron overload caused by blood transfusions in patients with certain hematological diseases. In 2005, deferasirox was approved by the FDA for the treatment of iron overload caused by blood transfusions during treatment in patients with chronic anemia 2 years of age and older.

This multicenter, prospective clinical trial was conducted to evaluate the safety and efficacy of deferasirox in patients with low- or intermediate-risk-1 myelodysplastic syndrome (MDS).

The study found that the reduction of serum ferritin was significantly positively correlated with the improvement of ALT (P <0.001). Baseline labile plasma iron (LPI) was elevated in 68 patients (39.3%). After 13 weeks, all patients with abnormal baseline LPI levels returned to normal. According to the International Working Group's 2006 criteria, 51 patients (28%) had improved hemograms, of which only 7 patients received growth factors or MDS. During the 3-year study, 138 (79.8%) patients discontinued treatment, 43 (24.8%) of whom discontinued treatment due to adverse events or disease progression, and 23 (13.2%) due to abnormal laboratory test values. The most common drug-related adverse events were gastrointestinal disturbances and increased serum creatinine. Twenty-eight patients died, but none were related to deferasirox treatment.

Deferasirox dispersible tablets are an oral active chelating agent that is highly selective for iron (Fe3+). It is a ligand with 3 protrusions that binds iron with high affinity in a 2:1 ratio. Although deferasirox has a very low affinity for zinc and copper, serum concentrations of these trace metals decreased to varying degrees after administration.

For more information, please contact Medical Companion Travel for details.